# **Effect of Gender on Lung Function and Patient-Reported Outcomes** in Patients with COPD Receiving Nebulized Glycopyrrolate Ohar JA, et al. Int J Chron Obstruct Pulmon Dis. 2020;15:995-1004



**KEY FINDINGS** 

Treatment with GLY 25 μg BID resulted in improvements in FEV,, SGRQ total score and EXACT-RS total score at 12 weeks were significantly greater in female patients compared with male patients. The safety profile of GLY was similar between genders.

Screening

1-3 weeks



**OBJECTIVE** 





Pooled data from GOLDEN-3 and -4 Phase III clinical trials

> Patients aged ≥40 years with moderate-to-very-severe COPD, grouped by gender

Randomized 1:1:1 to placebo, GLY 25 µg BID, or GLY 50 µg BID



**Double-blind treatment period** Follow-up 5-7 days




Continuation of background LABA  $\pm$  ICS permitted




**RESULTS** 

# **BASELINE DEMOGRAPHICS**



### **LUNG FUNCTION**

#### Trough FEV₁ improved with GLY 25 μg vs. placebo regardless of gender




GLY 25 µg produced significant and clinically important improvements in change from baseline in trough FEV₁ vs. placebo in both male and female patients




The difference in improvement in FEV<sub>1</sub> was numerically but not significantly greater in women (p=0.221)

# PATIENT-REPORTED OUTCOMES


SGRQ total score improved with GLY 25 µg vs. placebo regardless of gender




Improvements in EXACT-RS with GLY 25 µg vs. placebo was greater in female patients



# **SAFETY**









The safety profile of GLY 25  $\mu g$ was similar between genders. Incidences of AEs and SAEs were lower in GLY 25 µg vs. placebo treatment groups in both genders.